TCS Industries Limited (China-sourced API supplier) supplies Tamoxifen — API CAS 10540-29-1 for pharmaceutical B2B procurement — COA, MSDS, and technical documentation available on request.
> Overview
| Product Name | Tamoxifen |
|---|---|
| Structural Formula |  |
| CAS Number | 10540-29-1 |
| Molecular Formula | C26H29NO |
| Molecular Weight | 371.5 g/mol |
| InChIKey | NKANXQFJJICGDU-QPLCGJKRSA-N |
| SMILES | Available on request where applicable |
| Appearance | White to off-white crystalline powder |
| Purity / Grade | By agreed specification and batch COA |
| Storage | Store at controlled room temperature, protect from light |
Tamoxifen (CAS 10540-29-1) is a selective estrogen receptor modulator (SERM) with the formula C₂₆H₂₉NO (MW 371.51, free base). The citrate salt (CAS 54965-24-1) is used in pharmaceutical formulations. Tamoxifen acts as an estrogen antagonist in breast tissue and an estrogen agonist in bone and endometrium. It is used for treatment and prevention of estrogen receptor-positive breast cancer and is on the WHO Model List of Essential Medicines.
TCS Industries Limited, a Hong Kong-based trading and sourcing company, supplies Tamoxifen (free base and citrate salt) API in pharmaceutical grade for global procurement programs.
> Applications
Breast cancer treatment and prevention
Tamoxifen competitively binds the estrogen receptor, blocking estradiol-driven proliferation in ER-positive breast cancer cells. It is administered orally at 20 mg/day for 5–10 years as adjuvant therapy. Tamoxifen reduces breast cancer recurrence by 40–50% and mortality by 30% in ER-positive disease. Early Breast Cancer Trialists Collaborative Group (Lancet, 2011, 378:771–784) demonstrated in a meta-analysis of 20 trials that 5 years of adjuvant tamoxifen halved the annual breast cancer recurrence rate.
Prevention and other indications
Tamoxifen is FDA-approved for breast cancer risk reduction in high-risk women. It is also used for gynecomastia treatment, ovulation induction, and McCune-Albright syndrome in pediatric patients. Its mixed agonist-antagonist profile provides bone-protective effects (reduces fracture risk in postmenopausal women).
> Sourcing & Supply
TCS Industries Limited supports development, qualification and commercial purchasing discussions for Tamoxifen with buyers in Australia, New Zealand, Canada and South Korea.
- Evaluation and commercial quantities: 500 g samples for analytical qualification; 5 kg and 25 kg for production. Free base and citrate salt forms in pharmaceutical (USP/Ph.Eur.) grade available. DMF reference letters provided.
- Pallet quantities and production campaigns: repeat supply is coordinated against packaging, lead time, annual demand and destination-market import requirements.
> Quality & Documentation
Key specification parameters include assay (≥99.0% for free base, ≥99.0% for citrate), E/Z isomer ratio (predominantly Z-isomer, the active form), related substances (individual ≤0.3%, total ≤1.0%), loss on drying, residual solvents, heavy metals, and microbial limits. White crystalline powder (free base); white to off-white powder (citrate). Identity by HPLC, IR, and melting point. Meets USP (Tamoxifen Citrate), Ph.Eur. (Tamoxifeni citras), and BP. COA and MSDS are standard.
> Packaging
Tamoxifen citrate is a white to off-white crystalline powder. Standard packaging includes double PE-lined aluminium foil bags in fibre drums (5 kg, 10 kg, or 25 kg). Store at controlled room temperature (15–25 °C). Protect from light. Shelf life is typically 36 months. Labels and documents are checked before dispatch.
> Pricing & MOQ
Pricing is quoted by specification, packaging and destination. Common commercial discussions use 25 kg bag/drum formats, pallet quantities and production-campaign planning; smaller samples may be reviewed for qualified formulation teams.
> Regulatory & Compounding Context
Tamoxifen citrate is monographed in USP, Ph.Eur. (Tamoxifeni citras), BP, and JP. FDA-approved in 1977 (Nolvadex). On the WHO Model List of Essential Medicines. Multiple generic approvals worldwide. Listed in the FDA IID for oral dosage forms. Off-patent globally. DMF support available from qualified manufacturers.
> Alias Index
- INN: Tamoxifen
- CAS Number: 10540-29-1 (free base); 54965-24-1 (citrate)
- Formula: C₂₆H₂₉NO (MW 371.51, free base)
- Brand name: Nolvadex (AstraZeneca)
- ATC code: L02BA01
- Pharmacological class: Selective estrogen receptor modulator (SERM)
- Commercial request terms: tamoxifen citrate API, Nolvadex generic, SERM API, breast cancer API, TCS Industries Limited
> FAQ
Why is Tamoxifen given for 5 to 10 years?
Extended adjuvant tamoxifen (5–10 years) continues to reduce breast cancer recurrence beyond the treatment period (carryover effect). The ATLAS trial showed that 10 years of tamoxifen further reduced recurrence and mortality compared to 5 years in ER-positive breast cancer. Duration is balanced against endometrial cancer risk, which increases with prolonged use.
What documents are available for Tamoxifen orders?
COA and MSDS are standard for commercial discussions. COO, packing list, invoice and other import-support documents can be arranged according to order scope.
Do you supply Tamoxifen to Australia and Canada?
Yes. We support B2B buyers in Australia, New Zealand, Canada and South Korea, subject to route and document review.
Do you supply New Zealand and South Korea?
Yes. We review Australia, New Zealand, Canada and South Korea for project supply, import documents, packaging and logistics planning before quotation.
What is the Z-isomer requirement?
Tamoxifen exists as E and Z geometric isomers. The Z-isomer (trans) is the pharmacologically active antiestrogen. The E-isomer is weakly estrogenic. Pharmaceutical-grade tamoxifen must be predominantly Z-isomer (>99%). E/Z ratio is controlled during synthesis and monitored by HPLC in the release specification.
Is a DMF available for Tamoxifen Citrate?
Yes. Tamoxifen citrate is an off-patent API with extensive generic competition. TCS sources from manufacturers who maintain active DMFs with the FDA and ASMF/CEP submissions with EMA. COA, stability data, and DMF reference letters are provided for ANDA and generic dossier support.
Can you arrange samples before commercial purchasing?
Samples or evaluation quantities may be reviewed for qualified buyers after target specification, application and destination-market requirements are clarified.
How is Tamoxifen packaged for export?
Packaging is confirmed by quantity and material properties. Typical options include foil bags, HDPE containers, fibre drums, 25 kg bags or palletized export packaging.
Can buyer-defined specifications be reviewed?
Yes. Send the specification, methods, impurity limits and required documents. TCS can review feasibility before confirming quotation and lead time.
What payment terms are normally used?
Standard payment is 100% T/T before dispatch unless a different arrangement has been approved for an established commercial account.
What lead time should buyers expect?
Lead time depends on stock, batch size, document scope and destination. Available stock can move faster; made-to-order or pallet programs require longer planning.
What metabolic activation is required?
Tamoxifen is a prodrug. CYP2D6 converts it to endoxifen (4-hydroxy-N-desmethyltamoxifen), the primary active metabolite with 100× greater ER binding affinity. CYP2D6 poor metabolizers have lower endoxifen levels and potentially reduced efficacy. Pharmacogenomic testing for CYP2D6 status is recommended in some guidelines.
Last reviewed: June 2026
> Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.